Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

New Technique Speeds Up Whole-Body MRI for Children Without Sacrificing Image Quality, Study Finds

As we mark Childhood Cancer Awareness Month, we would like to highlight the progress achieved in the realm of cancer diagnostics. A recent study led by Dr. med. Paul-Christian Krüger and his team from the Universitätsklinikum Jena sheds light on an innovative approach to whole-body MRI in children and adolescents using an advanced sequence that significantly reduces the time needed for the imaging procedure without compromising the quality of the images.

Such steadfast dedication to securing young patients' safety and comfort is truly heartwarming. This commitment motivates researchers to continuously perfect and elevate diagnostic methods while paving the way for progress in the early detection and treatment of childhood cancer.

Learn more about this study with mint Lesion™.

Related Resources

Related Resources

Screenshot of a prostate lesion in mint Lesion

Streamline Prostate Cancer Screenings with Prostate.Carcinoma.ai in mint Lesion

The Prostate.Carcinoma.ai plug-in, developed by our partner FUSE-AI, is a powerful addition to mint Lesion, designed specifically to enhance prostate…

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing…

Image shows graphic related to study's research on iRECIST and RECIST

University Hospital Cologne: Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

A retrospective study conducted at University Hospital Cologne compared two criteria for assessing therapeutic response to immunotherapy: iRECIST and…